{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"68.5"},{"groupId":"OG002","value":"37.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Percentage of patients who were event free at 4 months","groups":[{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG000","title":"Pre-B ALL Relapse < 36 Mths From Dx (Chemotherapy) Age >21 Yrs"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG001","title":"Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG002","title":"Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG003","title":"T-cell ALL (Chemotherapy)"},{"description":"Re-Induction Block 1 patients receive liposomal vincristine sulfate , Prednisone, pegaspargase and Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine and L-Asparaginase. Patients receive Bortezomib on days 1, 4, 8 \\& 11 of Block 1 and days 1, 4, \\& 8 of Block 2.","id":"OG004","title":"T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"The analysis on this primary outcome is limited to pre-B ALL with age \\<= 21 years who relapsed \\< 36 months only (stratum 1 \\& 2) per protocol section 9.2.1.","reportingStatus":"POSTED","timeFrame":"4 months after enrollment","title":"Event Free Survival","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}